Introduction {#S5}
============

Of 40 million people living worldwide with a Human Immunodeficiency Virus (HIV) infection approximately 2.3 million are chronically co-infected with the Hepatitis C Virus (HCV) \[[@R1]\]. HIV/HCV co-infected patients demonstrate higher rates of neuropsychiatric illness (NI, such as generalized anxiety disorder, dysthymia, panic disorder, major depression and substance abuse disorder) relative to HIV mono-infected subjects or the general population \[[@R2],[@R3]\]. In previous research, we identified gene expression profiles significantly modulated in HIV/HCV co-infected patients who experienced pegylated interferon-α (PegIFN-α)-induced NI and were able to characterize the unique role of Interferon-stimulated-exonuclease-gene 20 kDa (ISG20) in linking PegIFN-α-related NI to distinct HCV treatment responses in patients co-infected with HIV and HCV \[[@R4],[@R5]\]. Interestingly, during this work, we detected 9 molecular markers (i.e., chromosome 9 open reading frame 167; formin binding protein 1; spectrin repeat containing nuclear envelope 1; lanosterol synthase; IKAROS family zinc finger 1; single stranded DNA binding protein 3; arginyl aminopeptidase; ARP2 actin-related protein 2 homolog; Ubiquitin-conjugating enzyme E2I) that were characterized by sustained expression differences pre and post therapy between patients who developed PegIFN-α-related NI and those who did not \[[@R5]\]. These gene expression patterns along with functional annotation analysis results using the Database for Annotation, Visualization and Integrated Discovery (DAVID) \[[@R6]\] strongly suggest that this 9-gene signature likely contains HIV- and/or HCV-linked biology that renders the central nervous system (CNS) more vulnerable for NI, especially in the presence of systemic interferon \[[@R5],[@R7]--[@R15]\]. Unfortunately, we were unable to validate these microarray data via real-time polymerase chain reaction (RT-PCR) as no peripheral blood mononuclear cell (PBMC) samples were available anymore from the HIV/HCV co-infected patients (N=28; 89% males; 50% African Americans; mean age: 46.5 years) enrolled in this study \[[@R5]\]. In an ultimate effort to evaluate reproducibility of these findings, we applied the same analytical and computational algorithms to peripheral whole blood (PB) samples collected from PegIFN-α naïve, HCV mono-infected patients (N=25; 64% males; 100% Caucasians; mean age: 43.6 years) who had been recruited for previous studies at the University Hospital in Essen (Essen, Germany). Despite the considerable heterogeneity of original study settings and demographics, a 2-step selection approach led to identification of formin binding protein 1 (FNBP-1) as a uniquely regulated marker in association with the development of NI in both cohorts. However, it has to be clear, that this analysis represents extension of previous work, which attempts to generate novel hypotheses underlying the molecular pathogenesis of HIV- and/or HCV-associated NI through a microarray data mining procedure. As modern standard HCV therapy consists exclusively of direct acting antivirals (DAA), these findings may still prove important to drive future investigation towards understanding the pathogenesis of NI in patients requiring type I IFN therapies for diseases such as chronic hepatitis B virus infection \[[@R16],[@R17]\], multiple sclerosis \[[@R17],[@R18]\] or melanoma \[[@R17],[@R19]\].

Study Subjects and Methods {#S6}
==========================

Study subjects {#S7}
--------------

25 therapy-naive patients with chronic HCV infection that were previously recruited at the University Hospital Essen (Essen, Germany) for microarray studies aimed to discover biomarkers for HCV-associated liver fibrosis and/or therapeutic response to subsequent PegIFN-α treatment (i.e., HCV elimination and drug-induced toxicity including NI) were considered for re-analysis for the purpose of this work. Inclusion and exclusion criteria, psychiatric evaluation and general study settings were applied as described elsewhere \[[@R20],[@R21]\]. Methods of two earlier studies with PegIFN-α naive HIV/HCV co-infected subjects (N=28) recruited at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH, Bethesda, Maryland, USA), which led to identification of FNBP-1 and provided foundation for this research, are published elsewhere \[[@R4],[@R5]\]. Overall, study subjects signed informed consents approved by the institutional review board prior to enrollment.

Microarray analysis {#S8}
-------------------

PB samples collected from HCV mono-infected patients (N=25) were subjected to microarray analysis (Affymetrix^®^ HG-U133A_2) as previously described \[[@R4],[@R5],[@R20]--[@R22]\].

First step {#S9}
----------

One-way-ANOVA (PARTEK Genomics Suite) was performed based on assigning HCV mono-infected patients (N=25) patients into two groups, i.e. those who developed NI and those who did not (NoNI); a Mean Fold Difference value (MFD) has been calculated for each selected gene before the first administration of PegIFN-α representing the absolute mean difference in gene expression (log~2~) between the groups. Since statistical comparisons between gene expression signals measured in different specimens (PB vs. PMBC) was intended, we applied an absolute MFD filter of ≥ 0.38 (log~2~) but relaxed the P value threshold from \<0.05 to ≤ 0.1 in order to increase power of bioinformatics analysis performance at baseline. Because induced expression signals were measured for each gene 12 h after the 1^st^ administration of PegIFN-α in HCV mono-infected patients (and not at the end of a 48 weeks treatment, as had been the case in HIV/HCV co-infected study participants) we set a MFD threshold of ≥ 0.38 (log~2~) as the only gene selection filter for analysis at this time point. Hence, four subsets (A, B, C, D) were formed including genes that passed these criteria ([Table 1](#T1){ref-type="table"}).

Second step {#S10}
-----------

Venn Diagrams were performed based on these four subsets with the intention to overlap significant results from the group comparison NI vs. NoNI pre and/or post treatment to identify common gene signatures between both cohorts ([Figure 1](#F1){ref-type="fig"}). Furthermore, two sets (E and F) including nine and nineteen unique genes, respectively, were found to have passed the selection cutoffs in the abovementioned contrasts.

Results {#S11}
=======

Using a combined statistical algorithm as described under METHODS, two subsets (E and F) representing a total of 28 unique genes were selected. Among those, only FNBP-1 was characterized by homologous expression patterns, i.e., upregulation, in association with NI in both cohorts, especially at baseline, which represents the best comparable condition between both studies, but also during PegIFN-α based treatment ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Moreover, FNBP-1 counts to molecular markers that demonstrate significant enrichment in various brain tissues (P\<0.01) according to functional annotation tool "DAVID" \[[@R5],[@R6]\].

The statistical variability witnessed between both cohorts may be attributed by differences in blood samples, RNA quality, racial type, and the co-incidence of HIV infection; the latter factor may influence differential regulation with respect to NI pathogenesis more drastically than HCV mono-infection \[[@R23]\].

Interestingly, correlation of FNBP-1 gene expression values between two registered probesets, i.e., the 212288_at and the 213940_s\_at, was relatively poor (HCV: r=0.29/P=0.145) or even inverse (HIV/HCV: r=−0.34/P=0.07) at baseline and post treatment in the HIV/HCV cohort (r=0.31/P=0.119, [Table 3](#T3){ref-type="table"}), likely due to expression of multiple transcript variants. Probesets, which are designated by the suffix "s_at", detect transcript variants sharing common sequence (<http://www.affymetrix.com/support/help/faqs/hgu133/faq_2.jsp>). Such splicing variants of FNBP-1 with functionally different responses in the CNS have been previously reported \[[@R24]\].

Discussion {#S12}
==========

Microarray analysis revealed that upregulation of FNBP-1 gene expression at baseline appears as a marker of a clinical state characterized by increased vulnerability for subsequent NI in association with HIV/HCV co-infection and to lesser degree to HCV mono-infection. Interestingly, in human samples, FNBP-1 has been found to be recruited to clathrin-coated pits in clathrin-mediated endocytosis (CME), which suggests the physiological role of FNBP-1 in this ubiquitous process \[[@R25]\]. In line with this observation, FNBP-1 is also reportedly involved in dynamin-mediated endocytosis in a clathrin-dependent as well as clathrin-independent manner \[[@R26],[@R27]\]. Importantly, inhibition of clathrin-dependent endocytosis has been shown to block uptake of IFN-α receptors resulting in attenuation of IFN-α-induced signaling, and thus, likely also of NI pathogenesis driven by IFN-α \[[@R28]\]. In agreement with these data, we found a consistently significant positive correlation between gene expression values of FNBP-1 and clathrin, heavy chain (CLTC; 200614_at) in the HIV/HCV co-infected (P~pre~\<0.043) as well as the HCV mono-infected cohort (P~pre~\<0.01); notably, CLTC gene depletion has been characterized as an effective method of inhibiting CME in cell lines \[[@R29]\]. The consistent correlation dynamics between FNBP-1, CLTC and NI in two independent cohorts supports the biological validity of this result.

Furthermore, it has been previously reported that symptoms of behavioral illness can be reliably reproduced in animals and humans by administration of cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNFα) \[[@R30]--[@R32]\]. Against this background, studies suggesting involvement of clathrin-mediated mechanisms in IL-1 internalization \[[@R33]\], intracellular trafficking and transcytosis of TNFα \[[@R34]\], as well as endocytosis of the IL-6 receptor complex \[[@R35]\] along with induction of pro-inflammatory cytokines, including IL-1, IL-6 and TNFα by PegIFN-α \[[@R36],[@R37]\], imply a multifaceted role of FNBP-1 in the pathogenesis of NI.

Moreover, a potential role of FNBP-1 with regard to NI may further derive from studies revealing the significant influence of serotonin on the activity of excitatory synapses in prefrontal cortex pyramidal neurons. In fact, serotonin regulates synaptic plasticity through a mechanism facilitating clathrin/dynamin-dependent internalization of ionotropic glutamate (AMPA) receptors \[[@R38]\]. The possibility that AMPA receptor trafficking also may be involved in the pathophysiology of neuropsychiatric disorders is suggested by recent studies showing the ability of abuse substances to elevate levels of the AMPA receptors in the ventral tegmental area as crucial for the development of behavioral sensitization \[[@R39]\]. Recently, FNBP-1 was reported to interact with sorting nexin 2 (SNX2), a molecular factor involved in several stages of intracellular trafficking \[[@R40]\], suggesting that FNBP-1 is also affecting receptor trafficking. Additionally, CME represents the primer mechanism of vesicle retrieval in hippocampal synapses \[[@R29]\], which indicates a further pathway of how FNBP-1 might be implicated in the regulation of CNS functions potentially relevant for the pathogenesis of psychiatric disorders.

Taken together, these data demonstrate that FNBP-1 plays a potential role in mediating immune-related neuropsychiatric illness. Moreover, the reported influence of FNBP-1 on monoamine pathways, which are considered of crucial importance in the pathogenesis and treatment of neuropsychiatric disorders \[[@R41]\], suggests further major involvement of this molecule in regulation of neuropsychological functions in the CNS.

Although not validated, which represents the major limitation of this work, here, we presented microarray data strongly arguing for intensifying research into the FNBP-1-related mechanisms that may be conferring risk for/resistance to interferon-induced neuropsychiatric events. Obviously, without striving for samples homology or including further control groups (i.e., HBV mono-, HBV/HIV co-infected, non-infected patients with IFN-α therapy and non-infected persons with primary psychiatric disorders, etc.) in proper study designs and without performing experimental/functional validation of microarray analysis results, it will be difficult to reach for evident mechanisms causing neuropsychiatric illness beyond the descriptive and/or hypothetical interpretation of these data.

As stated elsewhere, one part of background research, which set the stage for the work presented here, was funded with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E.
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###### 

Infection status, patient groups, statistical criteria and gene subsets along with gene counts per selected subset.

  -------------------------------------------------------------------------------------------------
  Infection\       Time   Study        Contrast   Selection criteria      Genes (N)   Gene subset
  (patients)                                                                          
  ---------------- ------ ------------ ---------- ----------------------- ----------- -------------
  **HIV/HCV**\     Pre    NIAID/NIH\   NoNI-NI    P\<0.05 and MFD\        \(83\)      A
  **(N=28)**              (MD, USA)               (log2) ≥ 0.38                       

  **HIV/HCV**\     Post   NIAID/NIH\   NoNI-NI    P\<0.05 and MFD\        \(131\)     B
  **(N=25)**              (MD, USA)               (log2) ≥ 0.38                       

  **HCV**\         Pre    UHE\         NoNI-NI    P≤0.1 and MFD (log2)\   \(96\)      C
  **(N=25)**              (Germany)               ≥ 0.38                              

  **HCV (N=25)**   Post   UHE\         NoNI-NI    MFD (log2) ≥ 0.38       \(134\)     D
                          (Germany)                                                   
  -------------------------------------------------------------------------------------------------

###### 

Comparison of FNBP-1 gene expression levels between both cohorts.

  --------------------------------------------------------------
  FNBP-1\     HCV (PB)\    P value   HIV/HCV (PBMC)\   P value
  212288_at   HG-U133A_2             HG-U133A          
  ----------- ------------ --------- ----------------- ---------
  **Pre**     NI\>NoNI     0.101     NI\>NoNI          0.006

  **Post**    NI\>NoNI     0.385     NI\>NoNI          0.048
  --------------------------------------------------------------

###### 

Linear regression analysis between FNBP-1 gene expression levels measured via different probesets: 213940_s\_at versus 212288_at.

  ---------------------------------------------------------------------------------
  FNBP-1     Probeset           HCV (PB)\   HIV/HCV (PBMC)\                 
                                HU133A_2    HU133A                          
  ---------- ------------------ ----------- ----------------- ------------- -------
  **Pre**    **213940_s\_at**   0.29        0.145             −0.34         0.070

  **Post**   (12 h)\            (12 h)\     (48 weeks)\       (48 weeks)\   
             0.63               0.0006      0.31              0.119         
  ---------------------------------------------------------------------------------
